The AGA Journals Blog highlights the latest discoveries in gastroenterology and hepatology research.

Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Share on facebook
Share on google
Share on twitter
Share on linkedin

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed.


Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective than placebo in inducing clinical remission at week 6 in patients with Crohn’s disease in whom previous treatment with tumor necrosis factor antagonists had failed.

However, at week 10, a higher proportion of patients given vedolizumab were in remission (26.6%) than of those given placebo (12.1%). Also, a higher proportion of patients with previous TNF antagonist failure given vedolizumab had a ≥100-point decrease in Crohn’s disease activity score at week 6 than those given placebo (39.2% vs 22.3%). Adverse events were similar between groups.

In the podcast, Sands says that these results show that patients with refractory disease might need to be treated for a longer period—it might not be clear until weeks 6–10 that vedolizumab will induce clinical remission.



Related Posts Plugin for WordPress, Blogger...
Kristine Novak

Kristine Novak

Leave a Replay

About The Author:

Dr. Kristine Novak

Dr. Kristine Novak

Dr. Kristine Novak is a science writer and editor based in San Francisco. She has extensive experience covering gastroenterology, hepatology, immunology, oncology, clinical, and biotechnology research discoveries.

Top Posts:


We never use your email for anything other than The AGA Journals Blog.